Breast cancer ORs (95% CIs) for the MTHFR C677T and A1298C polymorphisms
| Genotype . | Bivariate* . | . | Multivariate† . | . | Premenopausal*,‡ . | . | Postmenopausal*,‡ . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n§ . | OR (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | ||||||||
| 677 | ||||||||||||||||
| CC | 573/1211 | 1.00 | 534/1148 | 1.00 | 70/186 | 1.00 | 429/849 | 1.00 | ||||||||
| CT | 479/920 | 0.98 (0.83-1.15) | 441/866 | 0.97 (0.82-1.14) | 51/146 | 1.01 (0.64-1.59) | 365/648 | 0.96 (0.80-1.16) | ||||||||
| TT | 137/283 | 0.86 (0.67-1.09) | 131/271 | 0.85 (0.66-1.09) | 18/40 | 1.27 (0.65-2.47) | 103/207 | 0.80 (0.60-1.06) | ||||||||
| P | 0.28∥ | 0.25 | 0.57 | 0.16 | ||||||||||||
| 1298 | ||||||||||||||||
| AA | 741/1493 | 1.00 | 685/1405 | 1.00 | 78/236 | 1.00 | 562/1048 | 1.00 | ||||||||
| AC | 371/801 | 0.92 (0.79-1.08) | 349/764 | 0.92 (0.78-1.08) | 51/119 | 1.36 (0.89-2.07) | 274/568 | 0.88 (0.73-1.06) | ||||||||
| CC | 77/120 | 1.20 (0.88-1.65) | 72/116 | 1.18 (0.85-1.62) | 10/17 | 1.96 (0.84-4.55) | 61/88 | 1.18 (0.83-1.69) | ||||||||
| P | 0.93 | 0.96 | 0.06 | 0.78 | ||||||||||||
| Genotype . | Bivariate* . | . | Multivariate† . | . | Premenopausal*,‡ . | . | Postmenopausal*,‡ . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n§ . | OR (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | ||||||||
| 677 | ||||||||||||||||
| CC | 573/1211 | 1.00 | 534/1148 | 1.00 | 70/186 | 1.00 | 429/849 | 1.00 | ||||||||
| CT | 479/920 | 0.98 (0.83-1.15) | 441/866 | 0.97 (0.82-1.14) | 51/146 | 1.01 (0.64-1.59) | 365/648 | 0.96 (0.80-1.16) | ||||||||
| TT | 137/283 | 0.86 (0.67-1.09) | 131/271 | 0.85 (0.66-1.09) | 18/40 | 1.27 (0.65-2.47) | 103/207 | 0.80 (0.60-1.06) | ||||||||
| P | 0.28∥ | 0.25 | 0.57 | 0.16 | ||||||||||||
| 1298 | ||||||||||||||||
| AA | 741/1493 | 1.00 | 685/1405 | 1.00 | 78/236 | 1.00 | 562/1048 | 1.00 | ||||||||
| AC | 371/801 | 0.92 (0.79-1.08) | 349/764 | 0.92 (0.78-1.08) | 51/119 | 1.36 (0.89-2.07) | 274/568 | 0.88 (0.73-1.06) | ||||||||
| CC | 77/120 | 1.20 (0.88-1.65) | 72/116 | 1.18 (0.85-1.62) | 10/17 | 1.96 (0.84-4.55) | 61/88 | 1.18 (0.83-1.69) | ||||||||
| P | 0.93 | 0.96 | 0.06 | 0.78 | ||||||||||||
NOTE: aP value for a gene dosage term assigned 1, 2, and 3 for 0, 1, and 2 variant alleles, respectively.
Adjusted for age at blood draw and race and/or ethnicity.
Further adjusted for age at menarche, age at first birth, parity, and body mass index (83 cases and 129 controls were excluded due to missing covariates).
Premenopausal status was defined as still menstruating at baseline. Postmenopausal status was defined as menstruation stopping and natural menopause, bilateral oopherectomy, or age >55 years at cohort entry. Women with a simple hysterectomy with age ≤55 years or who could not be classified into these groups were excluded (153 cases and 338 controls).
No. cases/no. controls.
P value for a gene dosage term assigned 1, 2, and 3 for 0, 1, and 2 variant alleles, respectively.